Letitia Dean, Mounjaro and the Questions Worth Asking

Why is Letitia Dean's name linked to Mounjaro, and does that tell us anything useful?

Celebrity weight-loss stories create enormous search traffic. Letitia Dean, best known for her long-running role in EastEnders, spoke publicly about her weight loss, and British media connected it to tirzepatide. That kind of coverage does one useful thing: it tells people that a medicine most had never heard of exists. It does a less useful thing too, which is to make Mounjaro sound like a shortcut a celebrity found and you can simply copy. That framing quietly sets the wrong expectation.

Mounjaro is a medicine made by Eli Lilly, approved by the MHRA and licensed in the UK for adults with a BMI of 30 or above, or 27 and above where a weight-related health condition is present. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber looks at your full health picture (medical history, current medicines, any conditions that would make treatment unsuitable) before anything is dispensed. The celebrity story is the beginning of the question, not the answer.

If you want to understand the pharmacology rather than the tabloid version, including what researchers are learning about tirzepatide's potential role in longevity, the full tirzepatide overview on this site covers how the dual-receptor mechanism works in plain language.

What does Mounjaro actually do, and how is it different from the other weight-loss injections in the headlines?

Mounjaro activates two receptors (GIP and GLP-1) that play a role in regulating appetite, blood sugar and how quickly the stomach empties. Other injectable weight-loss medicines currently licensed in the UK (including Wegovy, which contains semaglutide) act on the GLP-1 pathway alone. The dual action is what makes tirzepatide the only medicine of its kind licensed for weight management in the UK.

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults using tirzepatide at the highest dose lost an average of around 20–21% of their body weight over 72 weeks, alongside a reduced-calorie diet and increased activity. Those figures are from a controlled clinical trial, not a celebrity profile, and they come with the same caveat: results vary between individuals, and the medicine is not a replacement for the lifestyle work.

Treatment starts at a 2.5mg dose, a pen designed to let your system adjust before the dose is gradually increased by a prescriber. The Mounjaro treatment page sets out the full dose schedule in context.

Can you get Mounjaro privately in the UK, and what does that process look like?

Yes, private prescription access is legal and established. The route is straightforward in structure: you complete a clinical consultation, a prescriber reviews it personally, and if treatment is appropriate, the medicine is dispensed from a pharmacy registered with the General Pharmaceutical Council. There are no referrals, no waiting lists, and no need to qualify under the NHS phased eligibility criteria (which at present require a BMI of 40 or above alongside several specific health conditions).

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it comes in, a real clinician, not automated triage software. Identity is verified, weight is confirmed on a live video call, and the prescriber checks for anything in your medical history that would affect safety or suitability. It is worth being clear on what that process protects you from: fake or mislabelled pens sold online without any clinical assessment have caused serious harm, and the MHRA has issued repeated public warnings about counterfeit weight-loss injections circulating in the UK. Buying through a pharmacy you can verify on the GPhC register is the check that matters.

If cost is a factor in your thinking, the guide to Mounjaro pricing in the UK explains what a legitimate private price includes and why the cheapest listing is not always the safest one.

What side effects should anyone considering Mounjaro know about?

The most common side effects are gastrointestinal: nausea, loose stools, constipation and reflux are regularly reported, particularly in the first weeks of treatment or after a dose increase. For most people they ease as the body adjusts, and anyone who has read about how Mounjaro may interact with conditions such as cystitis will know that staying well-hydrated and eating smaller meals helps on more than one front. The NHS tirzepatide page sets out the full side-effect profile with guidance on which symptoms need medical attention.

A few things need a prompt call to a doctor or 111. Severe, persistent stomach pain (especially pain that seems to travel to the back) needs to be taken seriously and assessed, given the known association between GLP-1 medicines and acute pancreatitis. Gallbladder symptoms, signs of dehydration, and any allergic reaction are also reasons not to wait. Your prescriber will go through this with you before treatment starts.

One misconception worth setting down gently: some people assume that because a medicine has celebrity associations it has somehow been made more glamorous or risk-free than ordinary medicines. It has not. Mounjaro carries a Black Triangle (▼) mark in the UK, meaning the MHRA requires additional monitoring of it because it is relatively new, and emerging research into areas such as Mounjaro and dementia risk is part of that ongoing picture. That is standard practice for recently licensed medicines and not a cause for alarm, but it is a reason to stay in contact with your prescribing team throughout treatment. Our FAQs page covers the questions our prescribers hear most regularly from people starting out.

If you would like to explore whether treatment could be appropriate for your situation, you can start a free consultation with the nume clinical team at any time.